-SEC Filing
Longboard Pharmaceuticals Completes Enrollment Of Phase 1b/2a PACIFIC Study Evaluating LP352 For The Treatment Of Developmental And Epileptic Encephalopathies
Enrolled 52 participants with Developmental and Epileptic Encephalopathies (DEEs) into the PACIFIC Study
Participants have a broad range of DEEs including Lennox-Gastaut syndrome, Dravet syndrome, SCN2A-related